ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Contribution of mammographic imaging after initial ultrasound in women with focal breast complaints-systematic review.European radiology · 2026Pooled it
- Determinants of stage at breast cancer diagnosis across different healthcare systems: an international multicentre cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- PRS-BCJournal of medical genetics · 2026Article
- Zip-Code Level Disadvantage as a Predictor of Metastatic Breast Cancer at Diagnosis and Delayed Treatment Initiation.Annals of surgical oncology · 2026Article
- Review
- Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over.Annals of surgical oncology · 2026Article
- Effects of trimodal prehabilitation on quality of life and negative emotions in patients with advanced triple-negative breast cancer.Frontiers in oncology · 2026Article
- Screen-Detected Breast Cancer Outcomes by Mammography Participation in Immediate Past Screening.JAMA network open · 2025Article
- Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance Expansion.JAMA network open · 2025Article
- Developing a website to help women aged 55 + incorporate risk in decision-making about breast cancer screening and prevention medications.Patient education and counseling · 2025Article
- Assessment of mammographic and ultrasonic signatures for differentiating benign and malignant breast structural distortions.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeControversy continues regarding the effect of screening mammography on breast cancer outcomes. We evaluated late-stage cancer rate and overall survival (OS) for different screening intervals using a real-world institutional research data mart.
methodsPatients having both a cancer registry record of new breast cancer diagnosis and prediagnosis screening history between 2004 and 2019 were identified from our institutional research breast data mart. Time interval between the two screening mammograms immediately preceding diagnosis and the time to cancer diagnosis were determined. Screening interval was deemed annual if ≤15 months, biennial if >15 and ≤27 months, intermittent if >27 months, and baseline if only one prediagnosis screen was known. The primary end point was late-stage cancer (TNM stage IIB or worse), and the secondary end point was OS. The association of screening interval and late-stage cancer was analyzed using multivariable logistic regression adjusting for prediagnosis characteristics. Proportional hazards regression was used for survival analysis. Potential lead time was analyzed using survival from a uniform fixed time point.
resultsIn total, 8,145 patients with breast cancer had prediagnosis screening mammography in the timeframe. The percentage of late-stage cancers diagnosed increased significantly with screening interval with 9%, 14%, and 19% late stages for annual, biennial, and intermittent groups (
conclusionAnnual mammographic screening was associated with lower risk of late-stage cancer and better OS across clinical and demographic subgroups. Our study suggests benefit of annual screening for women 40 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.